受取和解金、減価償却累計額、研究開発費 - 国際他2件
- 【期間】
| 年度 | 受取和解金 | 減価償却累計額 | 研究開発費 - 国際 | 利益剰余金（IFRS） | 支払利息 |
|---|
| 2007/12 | - | | - | | - | | - | | - | |
| 2008/12 | - | | - | | - | | - | | - | |
| 2009/12 | - | | -0.78億 | | - | | - | | - | |
| 2010/12 | - | | -0.96億 | 赤拡 | - | | - | | - | |
| 2011/12 | - | | -1.11億 | 赤拡 | - | | - | | - | |
| 2012/12 | - | | -0.7億 | 赤縮 | - | | - | | - | |
| 2013/12 | - | | -0.77億 | 赤拡 | - | | - | | - | |
| 2014/12 | -170億 | | -0.69億 | 赤縮 | - | | - | | - | |
| 2015/12 | - | | -0.78億 | 赤拡 | - | | - | | - | |
| 2016/12 | - | | - | | - | | - | | - | |
| 2017/12 | - | | - | | - | | - | | - | |
| 2018/12 | - | | - | | - | | 0.82兆 | | 67.5億 | |
| 2019/12 | - | | - | | 19.7億 | | 0.92兆 | +11.9% | 73.9億 | +9.4% |
| 2020/12 | - | | - | | 30.1億 | +52.6% | 0.97兆 | +5.3% | 112億 | +51.1% |
| 2021/12 | - | | - | | 23.7億 | -21.1% | 1.06兆 | +10.1% | 127億 | +13.8% |
| 2022/12 | - | | - | | - | | 1.17兆 | +9.5% | 123億 | -3.1% |
| 2023/12 | - | | - | | - | | 1.28兆 | +10% | 143億 | +16% |
